Nisekhkhuu, Algirmaa
Loading...
Товч нэр
Nisekhkhuu, Algirmaa
Бүтэн нэр
Nisekhkhuu Algirmaa
Латин нэр
Nisekhkhuu Algirmaa
Албан тушаал
Судлаач
3 results
Now showing 1 - 3 of 3
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Metabolic Syndrome in Women Who Have Polycystic Ovary Syndrome Related Infertility(Mongolian National University of Medical Sciences, 2021-10-03); ;Amarjargal Olzvoi ;Nyamsuvd Radnaabazar; Objective: The aim of the present study was to determine the prevalence of metabolic syndrome (MS) in infertile Mongolian women with polycystic ovary syndrome (PCOS) using the International Diabetes Federation (IDF) criteria. Methods: We used the case control retrospective study designs. Total 1340 infertile women enrolled in this study. Among the women, 114 were found with PCOS by Rotterdam’s criteria at the Infertility and reproductive department, National Center for Maternal and Child Health, between December 2018 and 2019. The IDF diagnostic criteria for metabolic syndrome (MS) was used. The PCOS patients were divided into the following groups: (1) cases (with MS, n = 42) and (2) controls (without MS, n = 72). Results: The average age, body mass index (BMI), and duration of infertility were 28.7 ± 4.1 years, 27.3 ± 5.2 kg/m² and 4.4 ± 3.1y, respectively. Among the patients 57.9% of them had oligomenorrhea, 22.8% had amenorrhea, 57.0% had primary infertility, 51.9% had hirsutism and 50.8% had acne. As a result of hormone assays, LH was 9.3±3.5mIU/ml, LH/FSH ratio was 1.6 ± 0.83 [0.1-3.6], and AMH was 6.1ng/ml ± 3.6 [2.9 - 21.0]. The prevalence of MS was 36.8%. The variables which include age (30.9 ± 4.9), body mass (75.9 ± 11.6kg), and also some metabolic parameters such as hypertension (133.6/88.4 ± 13.6 mm Hg), WC (94.1 ± 8.6 cm) and high triglyceride (1.8 ± 1.0 mmol/l) were observed in the MS group and compared to the without MS group. Conclusions: We found out that the prevalence of metabolic syndrome was 36.8% among infertile women with PCOS. Age, BMI, WC, amenorrhea, acne, and acanthosis nigricans were highly related to metabolic syndrome. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Mild Ovarian Stimulation for Infertility in Women with Polycystic Ovary Syndrome(Mongolian National University of Medical Sciences, 2022-04-01); ; ; Objective: The aim of this study was to explore the effect of clomiphene citrate (CC) on the cycle characteristics and outcomes of women with polycystic ovarian syndrome (PCOS) undergoing ovarian stimulation. Methods: This is a cross sectional study, and it was conducted at the tertiary-care medical center. This study included 55 PCOS patients and 54 patients without PCOS undergoing ovarian mild stimulation. In the study group (n = 55), CC and human menopausal gonadotropin (HMG) were administered simultaneously beginning on cycle day 3, while in the control group without PCOS (n = 54) a differing protocol treatment was used. The primary outcome measure was the stimulation day, HMG dose, number of dominant follicles, serum E2, LH, P4 in trigger day and number of oocytes. Secondary outcomes included the number of top-quality embryos, maturation rate, fertilization rate, cleavage rate, incidence of premature LH surge, and OHSS, biochemical and clinical pregnancy rate. Results: The study group received obviously a lower total HMG dose [470.54 ± 304.5 (375–975) vs. 500.00 ± 287.59 IU, but similar HMG duration. While the antral follicle count (AFC) was higher in the study group, the number of oocytes retrieved and top-quality embryos was remarkably less [5 (0 – 30) vs. 13 (0 – 42), 2 (0 –14) vs. 3.5 (0 – 15), p = 0.003, respectively]. The mature oocyte rate was higher in the study group (p = 0.036). No significant differences were detected in fertilization rate and cleavage rate between the 2 groups. CC had a positive influence (higher oocytes retrieved and top-quality embryos) on cycle characteristics, but might be correlated with the impaired IVF outcomes (lower E2, lower implantation rate) in PCOS patients undergoing IVF, when CC + HMG was used simultaneously. Conclusion: In women with PCOS, mild CC stimulation resulted in increased oocytes and viable embryos compared with the control group. The study regimens had a low incidence of OHSS. The results of the CC combined regimen provide new insights into the development of a more patient-friendly protocol for women with PCOS. However, this study needs to be continued on more samples in the future. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Өндгөвч уйланхайжих хамшинжтэй эмэгтэйчүүдийн оношилгоонд Анти-Мюллерийн дааврын ач холбогдлыг үнэлэх нь(2021-03-13); ;О.Амаржаргал ;Г.Баттулга ;Б.БолорчимэгД.МөнхцэцэгҮндэслэл: Өндгөвч уйланхайжих хамшинж (ӨУХШ) нь дэлхий дахинд нөхөн үржихүйн насны эмэгтэйчүүд (НҮНЭ)-ийн дунд оношлогдох шалгуураас хамаараад 4-18% тохиолддог нөхөн үржихүй, дотоод шүүрлийн эмгэг юм1. Зорилго: Үргүйдэлтэй эмэгтэйчүүдийн дунд ӨУХШ-ийн тохиолдлыг илрүүлэн, АМH-ын оношилгооны ач холбогдлыг тодорхойлох. Зорилт: 1. Үргүйдэлтэй эмэгтэйчүүдийн дунд ӨУХШ-ийн тохиолдлыг тодорхойлох. 2. ӨУХШ-тэй эмэгтэйчүүдийн оношилгоонд АМH-ын ач холбогдлыг үнэлэх. Арга, аргачлал: Судалгааг Эх, хүүхдийн Эрүүл Мэндийн Үндэсний Төв (ЭХЭМҮТ)ийн Эх барих, эмэгтэйчүүдийн эмнэлэг (ЭБЭЭ)-ийн Үргүйдэл, Нөхөн Үржихүйн Төв (ҮНҮТ)-өөр 2018 оны 12 сараас 2019 оны 12 сарын хооронд үйлчлүүлсэн нийт 1334 үргүйдэлтэй эмэгтэйд Роттердамын шалгуураар ӨУХШ оношлогдсон 116 тохиолдлоос мэдээлэл дутуу 2 тохиолдлыг хасч 114 тохиолдлыг дагаж судаллаа. Судалгааг явуулахдаа АШУҮИС-ийн Эрдэм шинжилгээний ёс зүйн хороо болон ЭХЭМҮТийн өсзүйн салбар хорооноос зөвшөөрөл тус тус авсан болно. Үр дүн: Судалгааны хугацаанд 1334 үргүйдэлтэй эмэгтэйчүүдийн дунд ӨУХШ 8.7% (116) илэрсэн. ӨУХШ-тэй, үргүйдэлтэй эмэгтэйчүүдийн насыг бүлэглэн авч үзэхэд 25-29 насныхан 43.9%, 30-34 нь 30.7%, нь, 20-24 17.5% байсан бол 35-39 насныхан 7.9%-ийг эзэлж байна. Дүгнэлт: 1. Үргүйдэлтэй эмэгтэйчүүдийн 8.7%-д нь ӨУХШ тодорхойлогдлоо. Энэ нь бусад улс орны тархалттай ойролцоо түвшинд байна. 2. Роттердамын шалгуур бол ӨУХШ-ийн оношилгооны суурь болох бөгөөд харин АМH нь эдгээр шалгуур үзүүлэлт дээр нэмэлт мэдээлэл бүхий тоон биомаркер болж чадаж байгааг бидний судалгааны үр дүн харууллаа. Гэвч энэ үр дүнг батлахын тулд илүү өргөн цар хүрээтэй судалгааны ажлыг хийх шаардлагатай юм.
